APUS vs POOL · $2.4M cap vs P/E 18, rev $5.31B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Pool Corporation (POOL) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Pool Corporation (POOL) is a industrial distribution company listed on NASDAQ.
APUS does not have a complete income-statement cache yet.
Latest reported POOL revenue for 2024-12-31 was $5.31B. Net income was $434.3M. Revenue was up 429.5% from 2023-12-31 to 2024-12-31. POOL currently screens at market cap $7.08B and trailing P/E 17.9.
APUS currently screens at market cap $2.4M. POOL currently screens at market cap $7.08B and trailing P/E 17.9.
Not investment advice. Open the APUS and POOL stock pages for the full models.
Not investment advice.